Drug Type Bispecific T-cell Engager (BiTE)  | 
Synonyms Anti-CD3/anti-PD-1 bispecific antibody, EX 105, EX-105 + [1]  | 
Target  | 
Action inhibitors, stimulants  | 
Mechanism CD276 inhibitors(CD276 antigen inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhaseIND Approval  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | IND Approval | China   | 15 Mar 2023 | |
| Pancreatic Cancer | Preclinical | United States   | 30 Jan 2022 | |
| Pancreatic Cancer | Preclinical | China   | 30 Jan 2022 | 






